Gallagher Capital Advisors LLC Invests $4.05 Million in Pfizer Inc. (NYSE:PFE)

Gallagher Capital Advisors LLC bought a new stake in Pfizer Inc. (NYSE:PFE) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 152,613 shares of the biopharmaceutical company’s stock, valued at approximately $4,049,000. Pfizer comprises 3.0% of Gallagher Capital Advisors LLC’s holdings, making the stock its 11th biggest holding.

Other institutional investors have also recently bought and sold shares of the company. Lauterbach Financial Advisors LLC grew its position in Pfizer by 40.7% in the 4th quarter. Lauterbach Financial Advisors LLC now owns 47,947 shares of the biopharmaceutical company’s stock worth $1,272,000 after purchasing an additional 13,881 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Pfizer by 3.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,515,622 shares of the biopharmaceutical company’s stock worth $66,739,000 after buying an additional 88,527 shares during the last quarter. Sowell Financial Services LLC boosted its holdings in shares of Pfizer by 2.6% in the 4th quarter. Sowell Financial Services LLC now owns 180,359 shares of the biopharmaceutical company’s stock worth $4,785,000 after acquiring an additional 4,581 shares in the last quarter. AlphaQuest LLC boosted its stake in Pfizer by 26.1% in the fourth quarter. AlphaQuest LLC now owns 24,083 shares of the biopharmaceutical company’s stock worth $639,000 after purchasing an additional 4,987 shares in the last quarter. Finally, Roberts Glore & Co. Inc. IL grew its holdings in Pfizer by 4.2% during the 4th quarter. Roberts Glore & Co. Inc. IL now owns 40,993 shares of the biopharmaceutical company’s stock worth $1,088,000 after acquiring an additional 1,649 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the subject of several research analyst reports. StockNews.com cut shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. UBS Group reduced their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Wolfe Research initiated coverage on Pfizer in a research note on Friday, November 15th. They issued an “underperform” rating and a $25.00 target price for the company. Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Finally, Truist Financial dropped their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Stock Performance

PFE opened at $26.71 on Monday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market cap of $151.35 billion, a price-to-earnings ratio of 18.94, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The business has a 50 day moving average of $26.30 and a 200-day moving average of $27.23.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.10 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, March 7th. Investors of record on Friday, January 24th were given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 6.44%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend was Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is currently 121.99%.

Insider Activity

In other news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.